Relationship between Serum Dehydroepiandrosterone Levels and Heart Ejection Fraction in Heart Failure Patients

Rima Hayyu Chrisnanda, M. Robiul Fuadi, S.P. Edijanto, M. Yusuf

Abstract


Cardiovascular disease is still a serious problem in the world of health. Life expectancy after being diagnosed with heart
failure is 50% and 10% for 5 and 10 years. Steroid hormones such as Dehydroepiandrosterone (DHEAS) have
cardioprotective effects by inhibiting the formation of atherosclerotic plaque, pulmonary artery vasodilators, and protecting
cardiomyocytes. DHEAS levels decrease with age. Decreased DHEAS levels are associated with an increased risk of
cardiovascular disease. This study aimed to know the relationship between DHEAS levels in serum and ejection fractions in
heart failure patients. This cross-sectional study used a sample of 34 people aged > 30 years who had been diagnosed with
heart failure by a specialist in the Department of Cardiology and Vascular Medicine. The diagnosis of heart failure uses
Echocardiography to determine the ejection heart fraction. DHEAS levels were taken from venous blood and examined
using the CLEIA method with an IMMULITE device (Siemens Healthineers, Germany). Statistical analysis was performed by
Spearman correlation test, with a significance level of p < 0.05. Thirty-four research subjects found that 13 patients had an
ejection fraction of 40% (Heart Failure with Reduced Ejection Fraction/HFrEF), 12 patients had an ejection fraction of 41-49%
(borderline) and 9 patients had an ejection fraction of ≥ 50% (Heart Failure with Preserved Ejection Fraction/HFpEF).
Spearman correlation test results obtained a correlation coefficient or r=0.357 with a value of p=0.038, which meant there
was a significant relationship between DHEAS with ejection fraction (p < 0.05). The lower the DHEAS level, the ejection
fraction would also be lower. Further with age, DHEAS levels get lower. The lower the DHEAS level, the lower the ejection
fraction.


Keywords


Dehydroepiandrosterone, DHEAS, ejection fraction, heart failure

Full Text:

PDF

References


Mannella P, Simoncini T, Caretto M, Genazzani AR.

Dehydroepiandrosterone and cardiovascular disease.

Italy, Elsevier Inc, 2018; 108.

Kementerian Kesehatan Republik Indonesia. Riset

kesehatan dasar. 2013; 88–94.

N Sen, S Tanwar, A Jain, J Sharma, RK Gorkhroo, A

Mehta, B Kalra. Assessment of testosterone/estradiol

ratio, DHEA-S level and correlation with coronary

inflammatory markers IL-1 & 6, TNF-1 and hsCRP

predict 5 years risk of cardiovascular disease in men.

European Heart Journal, 2019; 40: 746-781.

Jia X, Sun W, Hoogeven R, Nambi V, Virani S, et al.

Association of plasma Dehydroepiandrosterone

sulphate (DHEAS) with incident heart failure in older

men and women. Journal of the America College of

Cardiology, 2020; 75: 126-132.

Münzel T, Camici GG, Maack C, Bonetti NR, Fuster V,

Kovacic JC. Impact of oxidative stress on the heart and

vasculature: Part 2 of a 3-part series. J. Am. Coll.

Cardiol, 2017; 70: 212–229.

Jimerez MC, Tucker KL, Rodriguez F, Porneala B, Meigs

JB, Lopez L. Cardiovascular risk factor and

Dehydroepiandrosterone sulphate among Latinos in

the Boston Puerto Rico Health Study. Journal of the

Endocrine Society, 2019; 3: 291-303.

Macini A, Fuvuzzi AM, Bruno C, Nicolazzi MA, Vergani

E, et al. Anabolic hormone deficiencies in heart failure

with reduced or preserved ejection fraction and

correlation with plasma total antioxidant capacity.

International Journal of Endocrinology, 2020; 20: 1-8.

Vigue MJ, Rossier MF. In-vivo and in-vitro evidences of

Dehydroepidrosterone on the cardiovascular system.

Int J Endocrinol Metab, 2015; 13(2): e24660.

Bu B Yeap, Girish Dwivedi. Androgens and heart

failure: New observation illuminating in ageing

condrum. The Journal of Clinical Endocrinology and

Metabolism, 2020; 02597.

Aoki K, Terauchi Y. Effect of DHEAS on diabetes

mellitus and obesity. Japan, Elsevier Inc, 2018; 108.

Leff-Gelman P, Flores-Ramos M, Carraso AEA, Lopez

M, Takashima MF, et al. Cortisol and DHEAS level in

pregnant women with severe anxiety. BMC Psychiatry,

; 393.

Kumi H, Ohira T, Nagayoshi M, Kajiura M, Imano H,

et al. Dehydroepiandrosterone-sulphate is associated

with cardiovascular reactivity to stress in women.

Journal of Psychoneuroendocrinology, 2016; 69:

–22.

Ting WT, Chen Y, Zhou Y, Adi D, Zheng YY, et al.

Prognostic value of Dehydroepiandrosterone sulphate

for patients with cardiovascular disease: A systematic

review and meta-analysis. Journal of the American

Heart Association, 2017; 6(5): 1–13.

Perhimpunan Dokter Spesialis Kardiovaskular

Indonesia (PERKI). Pedoman tatalaksana gagal

jantung. Buku pedoman tatalaksana gagal jantung. Ed

pertama., Jakarta, PERKI, 2015; 14–27.




DOI: http://dx.doi.org/10.24293/ijcpml.v27i2.1664

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.